Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease

@article{Schirinzi2017LevelsOA,
  title={Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease},
  author={Tommaso Schirinzi and Giulia Di Lazzaro and Giulia Sancesario and Vito Luigi Colona and Eugenia Scaricamazza and Nicola Biagio Mercuri and Alessandro Martorana and Giuseppe Sancesario},
  journal={Journal of Neural Transmission},
  year={2017},
  volume={124},
  pages={1621-1625}
}
Experimental data suggest that the cerebrospinal fluid (CSF) dynamic is involved in the clearance of beta-amyloid, a key event in the pathogenesis of Alzheimer’s disease (AD). At this regard no evidence still exists in vivo. In this study we explored the relationships between CSF pressure and AD pathology, as measured with CSF core biomarkers. We enrolled 16 patients with probable AD and 21 controls, collecting demographics, clinical data, CSF opening pressure and CSF levels of beta-amyloid-42… 
Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
TLDR
These findings, albeit preliminary, indicate that brain-derived peptides may change in parallel in both peripheral blood and CSF of PD patients, eventually even in association with some clinical features.
How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging
TLDR
Preliminary findings suggested that, in normal subjects, systemic comorbidity might increase CNS oxidative stress and, together with aging, contribute to develop an Alzheimer’s disease-like biochemical profile.
Amyloid-β42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease.
TLDR
The novel Aβ42/NG ratio couples either presynaptic or postsynaptic markers of synaptic dysfunction, representing a potential global index of synaptopathy, useful to track cognitive functions in PD.
Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy
TLDR
It is demonstrated that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker.
Diagnosis of neurodegenerative dementia: where do we stand, now?
TLDR
The limitations and drawbacks in wide application of CSF biomarkers for diagnosing degenerative dementias, and on the role of laboratory medicine to convey these biomarkers from "research" toward "clinical practice" are discussed.
Association between physical activity and dementia’s risk factors in patients with Parkinson’s disease
TLDR
It is preliminarily demonstrated that a high level of PA is associated with a more favourable profile of PDD risk factors, in terms of both mood disturbances and CSF markers of neurodegeneration.
Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and Its Application in Urine Samples
TLDR
An indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) to detect Aβ1-42 by using a polyclonal antibody from alpaca, an application used in urine samples is developed and can be used for detecting the early stages of AD.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
TLDR
Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain and the combination of abnormally low CSF Abeta 42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy.
CSF biomarkers predict a more malignant outcome in Alzheimer disease
TLDR
A subgroup of patients with Alzheimer disease with extreme levels of CSF biomarkers exhibits worse clinical outcomes over time, including faster progression of cognitive deficits, no response to ChEI treatment, and a higher mortality.
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.
TLDR
Differences in VV may be an important confounder in interpreting CSF Aβ42 levels, and their combination, either corrected for VV/TIV ratio or not, was determined by ROC analysis.
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
TLDR
The rationales behind and the diagnostic performances of the core cerebrospinal fluid biomarkers for AD, namely total tau, phosphorylated tau and the 42 amino acid form of amyloid-β are presented.
Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow
TLDR
A direct and positive link between vascular and parenchymal Aβ; both can be modulated by CBF is revealed; both significantly exacerbate CAA and amyloid pathology.
Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease
TLDR
Elevated CSF pressure (CSFP), consistent with very early hydrocephalus, is reported, in a subset of AD patients enrolled in a clinical trial of chronic low-flow CSF drainage, and AD-NPH patients were significantly younger and significantly less demented on the Mattis Dementia Rating Scale.
Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State
TLDR
The role of CSF Aβ levels in light of experimental, clinical pathologic, and electrophysiological results in AD and other pathological entities are discussed to put in a correct frame the value of Aβ changes.
More advanced Alzheimer's disease may be associated with a decrease in cerebrospinal fluid pressure
TLDR
It is hypothesized that more advanced AD may be associated with a decrease in CSFP, and reduced CSFP among a group of AD patients could provide a clue towards a better understanding of the high rate of comorbidity reported between AD and glaucoma.
Alzheimer's disease
...
...